NovoCure (NVCR) Equity Average (2015 - 2026)

NovoCure has disclosed Equity Average across 12 years of filings, most recently posting $335.6 million for Q1 2026.

• Equity Average for Q1 2026 came in at $335.6 million, down 7.06% year-over-year; the trailing twelve-month figure through Mar 2026 was $335.6 million (down 7.06% YoY), and the FY2025 annual result was $350.3 million, down 3.05% from the prior year.
• Equity Average came in at $335.6 million for Q1 2026 at NovoCure, down from $340.9 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $443.5 million in Q3 2022 to a low of $335.6 million in Q1 2026.
• The 5-year median for Equity Average is $361.3 million (2024), against an average of $386.7 million.
• Across the five-year window, Equity Average grew 14.06% in 2022 and decreased 17.34% in 2024, its largest moves.
• NovoCure's Equity Average stood at $443.3 million in 2022, then slipped by 14.71% to $378.1 million in 2023, then retreated by 4.66% to $360.5 million in 2024, then fell by 5.43% to $340.9 million in 2025, then declined by 1.56% to $335.6 million in 2026.
• The last three Equity Average figures came in at $335.6 million (Q1 2026), $340.9 million (Q4 2025), and $345.4 million (Q3 2025), per Business Quant data.